Medtronic of Canada, Ltd.

Medtronic of Canada, Ltd.

October 25, 2010 06:00 ET

Medtronic Launches Improved Delivery System in Canada for Minimally Invasive Treatment of Thoracic Aortic Aneurysms

New Valiant® Captivia™ Stent Graft System Features Tip Capture for Enhanced Control During Deployment; Hydrophilic Coating Facilitates Iliac Access and Delivery

BRAMPTON, ONTARIO--(Marketwire - Oct. 25, 2010) - Adding to its market-leading portfolio of innovative medical technology for endovascular aortic repair (EVAR), Medtronic, Inc. (NYSE:MDT), announced today the Canadian launch of the Captivia(TM) Delivery System for the Valiant(R) Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta. The Captivia Delivery System has been available internationally since the fall of 2009 and was approved by Health Canada on August 3, 2010.

The Captivia Delivery System features tip capture for enhanced control of the Valiant Thoracic Stent Graft during deployment and a hydrophilic coating applied to the graft cover to facilitate iliac access and delivery through patients' vasculature. The new Valiant Captivia system enables physicians to treat a wide range of anatomies with a highly conformable stent graft, with accuracy and ease of delivery to achieve optimal clinical results. Both the Valiant Thoracic Stent Graft and Captivia Delivery System are investigational in the United States, where their use is limited to clinical trials approved by the U.S. Food and Drug Administration.

Dr. Francois Dagenais, cardiac surgeon at the Institut universitaire de cardiologie et de pneumologie de Québec in Quebec City, has performed 17 Valiant Thoracic Stent Graft implantations with the Captivia Delivery System. Dr. Dagenais is a global thought leader on thoracic endovascular repair and has pioneered this non-invasive treatment in Canada.

"The Captivia delivery system for the Valiant thoracic endograft allows for precise deployment, explained Dr. Dagenais," Especially within the high cardiac output and angulated aortic arch the Captivia system minimizes the "windsock effect" and the asymmetric deployment occasionally encountered in this procedure. Such a controlled release mechanism may reduce embolic dislodgement by reducing arch manipulation and avoid inadvertent arch branch coverage. In addition, the Captivia Valiant endograft is covered with a hydrophilic coating facilitating insertion of the endograft in tight or tortuous iliac anatomy."

Indicated for the treatment of a variety of thoracic aortic lesions, the Valiant Thoracic Stent Graft has emerged as the minimally invasive "system of choice" for thoracic endovascular aortic repair (TEVAR) outside the United States. In four years of clinical experience, more than 15,000 patients worldwide have received the Valiant Thoracic Stent Graft. 

"Given the widespread acceptance and growing use of our Valiant Thoracic Stent Graft, the Captivia Delivery System represents an enhancement that provides physicians with outstanding ease of access and delivery, as well as deployment accuracy and control," said Tony Semedo, vice president and general manager of Endovascular Innovations, part of the CardioVascular business at Medtronic. "Combined with the Valiant Thoracic Stent Graft, which retains its hallmark attribute of conformability, the new system will expand endovascular treatment to more patients with complex aortic disease."

A pioneer of EVAR, Medtronic has been an innovator and leader in the stent graft industry since the 1990s, with more than 175,000 patients treated with its devices. The company offers the broadest portfolio of stent grafts. Among these are the Talent(R) Abdominal and Thoracic Stent Grafts in the United States, as well as the Endurant(R) Abdominal and the Valiant(R) Thoracic Stent Grafts outside the United States.

Medtronic is committed to advancing the treatment of cardiovascular disease through collaboration with leading clinicians, researchers and scientists worldwide.

About Medtronic

Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

About Medtronic of Canada Ltd. 

Medtronic of Canada sells, services and distributes Medtronic products in Canada: medical devices used in cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose and throat surgery. Medtronic of Canada employs over 420 Canadians, it is headquartered in Brampton, Ontario, has regional offices in Vancouver and Montreal and an atrial fibrillation (AF) ablation catheter manufacturing facility – Medtronic CryoCath – in the Montreal metropolitan area.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contact Information

  • Medtronic of Canada Ltd.
    Katherine Power
    Public Relations
    1-800-217-1617 ext 3653